Quick Answer
Tevogen Bio Holdings Inc. reported Diluted EPS of $8.08 per share (loss) for fiscal year 2025.
Tevogen Bio Holdings Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$8.08 | -130.9% |
| 2024 | -$3.50 | -43.4% |
| 2023 | -$2.44 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.03 | +0.0% | +0.0% |
| June 30, 2025 | -$0.03 | +25.0% | +57.1% |
| March 31, 2025 | -$0.07 | +73.1% | -133.3% |
| September 30, 2024 | -$0.03 | +0.0% | +25.0% |
| June 30, 2024 | -$0.04 | +77.8% | +84.6% |
| March 31, 2024 | -$0.26 | +0.0% | -766.7% |
| September 30, 2023 | -$0.03 | — | +83.3% |
| June 30, 2023 | -$0.18 | — | +30.8% |
- Tevogen Bio Holdings Inc. showed a decrease of -130.9% in Diluted EPS compared to the prior fiscal year.
- Over the 2023–2025 period, Tevogen Bio Holdings Inc.’s diluted eps has declined by 231.1% (from $2.44 per share (loss) to $8.08 per share (loss)).
- The most recent figure is from Tevogen Bio Holdings Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 31, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: